Last reviewed · How we verify
MT1988
At a glance
| Generic name | MT1988 |
|---|---|
| Sponsor | Monument Therapeutics Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis (PHASE1, PHASE2)
- Safety and PK of Multiple Doses of MT1988 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MT1988 CI brief — competitive landscape report
- MT1988 updates RSS · CI watch RSS
- Monument Therapeutics Limited portfolio CI